Juno Therapeutics vs Umlaut.bio
Juno Therapeutics vs Umlaut.bio, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Juno Therapeutics is on 66/100 and Umlaut.bio on 35/100.
Where each one leads
Juno Therapeutics
- our overall score: 66/100 against 35/100
- funding raised: $317M against $3.0M
Umlaut.bio
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Juno Therapeutics | Umlaut.bio |
|---|---|---|
| What it is | Biotechnology company focused on developing cancer immunotherapies. | Developing novel immunotherapies for cancer. |
| Category | Biotechnology, Pharmaceuticals, Cancer Immunotherapy, Cart | Biotechnology, Cancer, Immunotherapy, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2013 | 2022 |
| Headquarters | Seattle, United States | Cambridge, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Juno Therapeutics | Umlaut.bio |
|---|---|---|
| Total funding | $317M | $3.0M |
| Latest round | Series B | Pre-Seed |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Juno Therapeutics | Umlaut.bio |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 66/100 | 35/100 |
| Traction | 40/100 | 32/100 |
| Team | 90/100 | Not published |
| Community | 15/100 | Not published |
| Search visibility | 15/100 | 8/100 |
| Quality | 87/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | Not published | F (37/100) |
| Domain ratingLink authority, 0-100 | Not published | 7/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Juno Therapeutics | Umlaut.bio |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery, Bootstrap |
Juno Therapeutics vs Umlaut.bio: common questions
Which is better, Juno Therapeutics or Umlaut.bio?
On our 0-100 score Juno Therapeutics rates higher (66/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Juno Therapeutics and Umlaut.bio compare on the numbers?
Juno Therapeutics leads on our overall score (66/100 against 35/100), funding raised ($317M against $3.0M).
Read the full Juno Therapeutics review and pricing or the Umlaut.bio review and pricing. You can also browse other Juno Therapeutics alternatives we track.